Business
Results of General Meeting and Board Changes
Cellbxhealth plc announced that all resolutions were passed at its General Meeting, paving the way for the admission of 816,760,990 New Ordinary Shares to AIM, with the first admission expected on December 16, 2025, and the second on December 18, 2025, bringing the total voting rights to 1,139,402,658. The company also confirmed the permanent appointment of Peter Collins as Chief Executive Officer, transitioning from his interim role, and anticipates four board appointments in January 2026, subject to due diligence. Disclaimer*
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\n \nTHIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CELLBXHEALTH PLC.\n \n15 December 2025\n \nCELLBXHEALTH plc (\"the Company\")\n Results of General Meeting and Proposed Board Changes\n \n· All Resolutions duly passed by Shareholders at General Meeting\n· Subject to due diligence, four appointments to the Board anticipated in January 2026\n· Peter Collins transitions from Interim CEO to CEO\nGuildford, UK - 15 December 2025 - CELLBXHEALTH plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces that all Resolutions proposed at the General Meeting held earlier today were duly passed by Shareholders on a poll. The results of the votes will shortly be available on the Company's website.\nAccordingly, following the passing of all Resolutions, application has been made to the London Stock Exchange for a total of 816,760,990 New Ordinary Shares, issued in relation to the Fundraising, to be admitted to trading on AIM. First Admission will be in respect of 9,090,000 New Ordinary Shares and is expected to occur at 8.00 a.m. on or around 16 December 2025. Second Admission will be in respect of 807,670,990 New Ordinary Shares comprising the Second Tranche Placing Shares, the Subscription Shares, the Retail Offer Shares and the Additional Subscription Shares and is expected to occur at 8.00 a.m. on 18 December 2025 (or, in each case, such later time and/or date as Cavendish and the Company may agree (being no later than 8.00 a.m. on 16 January 2026).\nShare Capital Reorganisation\nAs outlined in the announcement of the Fundraising made by the Company ...